Showing results (171-180 of 347) with videos related to

Sort By:
Pageof 35
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2017
Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLLCorinna L Boeck, Daniel C Amberger, Fatemeh Doraneh-Gard, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2005
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavoneRichard D Verschoyle, Peter Greaves, Hong Cai, et al.
Immunology Letters|January 29, 2026
FOXN1 immunodeficiency detected by TREC-based newborn screening - a challenge of management?Lea Graafen, Arndt Borkhardt, Julian Reiß, et al.
The Journal of Clinical Investigation|May 9, 2009
Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferationKirsten Huck, Oliver Feyen, Tim Niehues, et al.
Urologic Oncology|September 5, 2012
Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancersGünter Niegisch, Judith Knievel, Annemarie Koch, et al.
Blood|November 11, 2006
MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death programDorothee Viemann, Katarzyna Barczyk, Thomas Vogl, et al.
Journal of Cell Science|November 19, 2009
Inhibition of the ER Ca2+ pump forces multidrug-resistant cells deficient in Bak and Bax into necrosisKatja Janssen, Sibylle Horn, Mathis T Niemann, et al.
Molecular and Cellular Biology|December 24, 2008
Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicitySubbareddy Maddika, Soumya Panigrahi, Emilia Wiechec, et al.
Pageof 35